Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage European companies.

Our current portfolio comprises biotech, medtech and diagnostics companies, all working to develop truly disruptive solutions for high unmet medical needs.

Dezima and Acerta, multi-billion Euro success stories

BioGeneration was co-founder and investor in two of the most successful biotech startups in Europe: Acerta Pharma and Dezima Pharma. Acerta Pharma develops a new drug for the treatment of hematologic malignancies (leukemia) and was sold to AstraZeneca for up to US$ 7 billion. Dezima Pharma is developing a treatment for of a cardiovascular disorder (dyslipidemia) and was sold to Amgen for a deal amount of up to US$ 1.5 billion.

Shaping new life-science ventures

Our varied and complementary experience has been gained from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

BioGeneration Venture’s portfolio company SurgVision acquired by Bracco Imaging

Oct 18, 2017

BioGeneration Ventures (BGV) completes its third successful exit from its second fund’s portfolio after Acerta Pharma and Dezima Pharma Bracco as the global leader in diagnostic imaging validates the leading position of SurgVision in the emerging field of image guided...

Mellon Medical secures € 6 million for market introduction

Oct 2, 2017

Nijmegen, The Netherlands, 2 October 2017 – Mellon Medical, a Dutch MedTech developer of a platform technology for suturing with one hand, has raised € 6 million to advance its patented ground breaking global innovation in suturing technology. Leading product, the...

VarmX announces publication in Nature Communications of groundbreaking snake venom inspired approach to restore blood clotting in patients using anticoagulants

Sep 13, 2017

VarmX’s lead compound PseudoXa is based on snake venom properties, and addresses unmet medical need for safe and effective prevention and treatment of bleeding in patients taking factor Xa inhibitors Product development based on R&D performed by one of the world’s...

VarmX raises seed capital for development of modified blood coagulation factor X

Jun 27, 2017

Restoring blood clotting in patients using anticoagulants Seed funding from lead investor BioGeneration Ventures (BGV) and regional development agency InnovationQuarter Leading compound addresses high unmet need for effective prevention and treatment of severe...

News overview